Researchers at the NCI seek licensing and/or co-development research collaborations for an anti-viral polypeptide, Griffithsin, and its antiviral use against Hepatitis C, Severe Acute Respiratory Syndrome (SARS), H5N1, or Ebola.
The National Cancer Institute (NCI) and the National Institute of Child Health and Human Development (NICHD) seek research co-development partners and/or licensees for an antiviral treatment that can target SARS-Cov-2 replication in Covid-19 patients.
The National Cancer Institute (NCI) seek parties interested in collaborative research and/or licensing to further develop neutralizing nanobodies targeting Lassa virus as a possible treatment of Lassa virus infections.
Researchers at the National Cancer Institute (NCI) have developed nucleic-acid-based nanoparticle that can be adapted for RNA interference (RNAi), molecular imaging, or a combination thereof. The invention nanoparticles can be used as therapeutics in the treatment of cancer, whichthe NCI seeks parties to license or co-develop.
Three anti-HIV proteins- the antiviral lectin cyanovirin, the antiviral lectin griffithsin, and the monoclonal antibody 2G12- have been successfully expressed in the same rice seed. The co-expression allows for a low cost, stable production method for a triple anti-HIV microbicide for the prevention of HIV. The National Cancer Institute (NCI) seeks licensees for the invention microbicide and production method.
Researchers at the National Cancer Institute (NCI) have developed single domain human CD4 proteins to inhibit HIV-1 entry and improved human domain antibodies against HIV-1. Fusion proteins comprising the single domain CD4 and HIV-1 antibody can be used to effectively neutralize HIV-1 in vitro. Researchers seek licensing for development of these antibody-based therapeutics for the treatment of HIV-1.
The National Cancer Institute (NCI) Molecular Targets Laboratory is seeking parties interested in collaborative research to co-develop antiviral tropolone derivatives developed by systematic medicinal chemistry on the lead series.
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.
Researchers at the NCI have developed a method of improving the immune response in cancer immunotherapy by exploiting in the role of the Linker Adapted for T-Cell Signaling (LAT) molecule. The LAT molecular can enhance signaling through TCRs, thus, improving a patient’s own immune response to cancer or infectious diseases.
Researchers at the National Cancer Institute (NCI) have developed several novel small-molecule inhibitors directed against HPPK, a bacterial protein, as potential antimicrobial agents. The NCI seeks co-development partners or licensees to further develop these novel small-molecule HPPK inhibitors as broad-spectrum bactericidal agents.